Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Report

Gamma-Probe-Directed Lymphatic Mapping and Sentinel Lymphadenectomy in Primary Cutaneous Melanoma

Belhocine T.a · Piérard G.E.b · Gielen J.L.a · Daenen F.a · De Barsy C.a · Arrese J.E.b · Lahaye T.c · Rigo P.a

Author affiliations

aDivision of Nuclear Medicine and Departments of bDermatopathology and cPlastic Surgery, University of Liège, Belgium

Related Articles for ""

Dermatology 2002;204:355–361

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Report

Published online: June 21, 2002
Issue release date: 2002

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 9

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

Background: Radiotracer and blue-dye lymphatic mapping is a recommended combined method to guide sentinel lymphadenectomy and full regional lymph node dissection in selected patients with cutaneous melanoma. Objective: To evaluate the diagnostic accuracy and the prognostic value of gamma-probe-directed lymphatic mapping in cutaneous melanomas. Methods: Sixty-five stage I and II melanoma patients underwent gamma-probe-directed lymphatic mapping. Sentinel lymph nodes were studied by both conventional and immunohistochemical stainings. The median follow-up was 11 months. Results: Sensitivities of preoperative and intraoperative sentinel lymph node detection were 100 and 98%, respectively. Only 1 failure of detection and 1 missed same-basin metastasis were experienced in the axillary and cervical areas, respectively. Eleven patients (16.9%) had sentinel node metastases leading to adjuvant therapy. Conclusion: Gamma-probe-directed lymphatic mapping is useful for staging melanoma. However, in the expectation of a more specific identification of the sentinel lymph node, the standard protocol remains recommended for exploring the axillary and cervical areas. The histological examination supported in some cases by immunohistochemistry remains mandatory in all cases.

© 2002 S. Karger AG, Basel


References

  1. Piérard-Franchimont C, Uhoda I, Piérard GE: Cutaneous cancers in the Mosan region and Ardennes of Belgium. Dermatology 1999;198:187–191.
  2. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, Schroer K, Heller R, Lyman G, Rappaport D, Seigler HF, Balch C: The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759–767.
  3. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.
  4. Morton DL, Thompson JF, Essner R, Elashoff R, Stern AL, Nieweg OE, Roses DF, Karakousis CP, Mozillo N, Reintgen D, Wang H, Glass EC, Cochran A: Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial. Ann Surg 1999;230:453–465.
  5. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, Pijpers R, Morton DL: The Augsburg Consensus: Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000;89:236–241.
  6. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C-H, Lee JJ, Balch CM, Reintgen DS, Ross MI: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976 -983.
  7. Balch CM, Buzaid AC, Soong S, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–3648.
  8. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996;14:7–17.
  9. Reintgen DS: Regional nodal surgery for melanoma impacts recurrence rates and survival. Ann Surg Oncol 2000;7:80–81.
  10. Balch CM: The role of elective lymph node dissection in melanoma: Rationale, results, and controversies. J Clin Oncol 1988;6:163–172.
  11. Ramnath EM, Kamath D, Andrea B, Stall A, Kamath V, Cruse CW, Glass F, Messina J, Fenske N, Berman C, Ross MI, Cantor A, Cuthbertson D, Reintgen D: Lymphatic mapping for melanoma: Long-term results of regional nodal sampling with radioguided surgery. Cancer Control 1997;4:483–490.
  12. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, Balch CM, Ross MI: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253–2260.
  13. Wagner JD, Corbett L, Park HL, Davidson D, Coleman JJ, Havlik RJ, Hayes JT: Sentinel lymph node biopsy for melanoma: Experience with 234 consecutive procedures. Plast Reconstr Surg 2000;105:1956–1966.
  14. Cherpelis BS, Haddad FH, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, Fenske NA, Glass LF: Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol 2001;44:762–766.
  15. Gershenwald JE, Mansfield PF, Lee JE, Ross MI: Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma. Ann Surg Oncol 2000;7:160–165.
  16. Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN: Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 1993;2:303–308.
  17. Jacobs IA, Chevinsky AH, Swayne LC, Magidson JG, Britto EJ, Smith TJ: Gamma probe-directed lymphatic mapping and sentinel lymphadenectomy in primary melanoma: Reliability of the procedure and analysis of failure after long-term follow-up. J Surg Oncol 2001;77:157–164.
  18. Van der Veen H, Hoekstra OS, Paul MA, Cuesta MA, Meijer S: Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994;81:1769–1770.
  19. Pijpers R, Collet GJ, Meijer S, Hoekstra OS: The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma. Eur J Nucl Med 1995;22:1238–1241.
  20. Mudun A, Murray DR, Herda SC, Eshima D, Shattuck LA, Vansant JP, Taylor AT, Alazraki NP: Early stage melanoma: Lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe. Radiology 1996;199:171–175.
  21. Gogel BM, Kuhn JA, Ferry KM, Fisher TL, Preskitt JT, O’Brien JC, Lieberman ZH, Stephens JS, Krag DN: Sentinel lymph node biopsy for melanoma. Am J Surg 1998;176:544–546.
  22. Bongers V, Borel Rinkes IH, Barneveld PC, Canninga-van Dijk MR, van Rijk PP, van Vloten WA: Towards quality assurance of the sentinel node procedure in malignant melanoma patients. Eur J Nucl Med 1999;26:84–90.
  23. Albertini JJ, Cruse CW, Rapaport D, Wells K, Ross M, De Conti R, Berman CG, Jared K, Messina J, Lyman G, Glass F, Fenske N, Reintgen DS: Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217–224.
  24. Gennari R, Bartolomei M, Testori A, Zurrida S, Stoldt SH, Audisio RA, Geraghty JG, Paganelli G, Veronesi U: Sentinel node localization in primary melanoma: Preoperative dynamic lymphoscintigraphy, intraoperative gamma probe, and vital dye guidance. Surgery 2000;1271:19–25.
  25. Haigh PI, Lucci A, Turner R, Bostick PJ, Krasne DL, Stern SL, Morton DL: Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma. Cancer 2001;92:535–541.
  26. Vera DR, Wallace AM, Hoh CK, Mattrey RF: A synthetic macromolecule for sentinel node detection: 99mTc-DTPA-mannosyl dextran. J Nucl Med 2001;42:951–959.
  27. Vera DR, Wallace AM, Hoh CK: [99mTc]MAG3-mannosyl dextran: A receptor-binding radiopharmaceutical for sentinel node detection. Nucl Med Biol 2001;28:493–498.
  28. Phillips WT, Klipper R, Goins B: Use of 99mTc-labeled liposomes encapsulating blue dye for identification of the sentinel lymph node. J Nucl Med 2001;42:446–451.
  29. Gadd MA, Coit DG: Recurrence patterns and outcome in 1,019 patients undergoing axillary or inguinal lymphadenectomy for melanoma. Arch Surg 1992;127:1412–1416.
  30. Gadd MA, Cosimi AB, Yu J, Duncan LM, Yu L, Path DRC, Flotte TJ, Souba WW, Ott MJ, Wong LS, Sober AJ, Mihm MC, Haluska FG, Tanabe KT: Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999;134:381–387.
  31. Clary BM, Brady MS, Lewis JJ, Coit DG: Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2000;233:250–258.
  32. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB: Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000;87:484–489.
  33. Piérard GE, Piérard-Franchimont C, Claessens N, Arrese JE: Cutaneous melanoma and the Mosan Study Group of Pigmented Tumors: A step forward to trace invisible skin cancers and to offer better treatments. Rev Méd Liège 2001;56:S1–S6.

Article / Publication Details

First-Page Preview
Abstract of Report

Published online: June 21, 2002
Issue release date: 2002

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 9

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.